Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07287189 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

A Phase 2 study of Duchenne Muscular Dystrophy and Neuromuscular Diseases, sponsored by Satellos Bioscience.

Recruiting
Registry status
Phase 2
Development phase
51
Enrollment target
18
Study locations

NCT07287189 is a Phase 2 study of Duchenne Muscular Dystrophy and Neuromuscular Diseases that is actively recruiting participants, run by Satellos Bioscience. The registered enrollment target is 51 participants, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (88% lower). The trial reports 18 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07287189, a Phase 2 study of Duchenne Muscular Dystrophy and Neuromuscular Diseases, is actively recruiting participants, sponsored by Satellos Bioscience.

RECRUITING
Registry status
Phase 2
Development phase
51 participants
Enrollment target
18
Study locations

Study Summary

Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.

Conditions Studied

Duchenne Muscular Dystrophy Neuromuscular Diseases Muscular Dystrophies DMD Duchenne

Interventions

  • DRUG Placebo
  • DRUG SAT-3247

Study Locations (18)

Other

  • Clinic of Neurology and Psychiatry for Children and Youth - Belgrade
  • University Children's Clinic Tirsova - Belgrade
  • Mother and Child Health Care Institute - Belgrade

California

  • University of California Los Angeles - Los Angeles

Colorado

  • Colorado Children's - Aurora

Illinois

  • Lurie Children's - Chicago

Kansas

  • University of Kansas - Kansas City

Maryland

  • Kennedy Krieger Institute - Baltimore

Massachusetts

  • UMass Memorial Medical Center - Worcester

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 51 participants
Start Date 2025-12-08
Est. Completion 2027-06-30
Phase Phase 2

Sponsor

Satellos Bioscience

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07287189

The ClinicalTrials.gov registry entry for NCT07287189 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 411-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (88% lower). The listed sponsor is Satellos Bioscience, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07287189 reports 18 study locations spanning 16 distinct geographic areas - top geographies include Other, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT07287189 about?

NCT07287189 is a clinical study titled "Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients". Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.

What is the current status of trial NCT07287189?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2025-12-08. Estimated completion is 2027-06-30.

What conditions does trial NCT07287189 study?

This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, Neuromuscular Diseases, Muscular Dystrophies, DMD, Duchenne.

What interventions are being tested in trial NCT07287189?

The interventions under investigation include: Placebo (DRUG), SAT-3247 (DRUG).

Who is sponsoring clinical trial NCT07287189?

This trial is sponsored by Satellos Bioscience, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07287189 being conducted?

This trial has 18 study locations across California, Colorado, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Duchenne Muscular Dystrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Duchenne Muscular Dystrophy

All registered trials for this condition

Neuromuscular Diseases

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.